Wise choice for mild to moderate
vascular dementia and Parkinson’s disease dementia
Rivastigmine is a cholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease and Parkinson's. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting.
The drug is eliminated through the urine, and appears to have relatively few drug-drug interactions.
It was patented in 1985 and came into medical use in 1997. It is available in Capsule form
Indications
- Rivastigmine is indicated for the treatment of mild-to-moderate dementia of the Alzheimer's type (AD).
- Rivastigmine is indicated for the treatment of mild-to-moderate dementia associated with Parkinson’s disease (PD).
Dosage & Administration
- Alzheimer’s Disease with dementia 1.5 mg -3 mg (BID)
- Parkinson’s Disease with dementia 1.5 mg -3 mg (BID)
Pharmacodynamics Properties
Rivastigmine, a cholinesterase inhibitor, inhibits both butyrylcholinesterase and acetylcholinesterase. It is thought to work by inhibiting these cholinesterase enzymes, which would otherwise break down the brain neurotransmitter acetylcholine.
